|
DE69942581D1
(de)
*
|
1998-05-25 |
2010-08-26 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung einer nucleinsäure enthaltenden kompositzusammenstellung
|
|
CA2361201A1
(en)
*
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
|
EP1097993A3
(en)
*
|
1999-11-05 |
2004-01-07 |
National Institute of Advanced Industrial Science and Technology |
Functional ribozyme chimeric molecules capable of sliding
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
CA2474822A1
(en)
*
|
2002-02-07 |
2003-08-14 |
University Of Utah Research Foundation |
Method for creating and using a treatment protocol
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
JP4868739B2
(ja)
*
|
2002-05-06 |
2012-02-01 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
核酸の送達法
|
|
JP2005529959A
(ja)
*
|
2002-06-14 |
2005-10-06 |
マイラス コーポレイション |
細胞へのポリヌクレオチドの伝達をするための新規な方法
|
|
WO2004011624A2
(en)
*
|
2002-07-31 |
2004-02-05 |
Nucleonics, Inc. |
Double stranded rna structures and constructs, and methods for generating and using the same
|
|
WO2004073631A2
(en)
*
|
2003-02-14 |
2004-09-02 |
Combinatorx, Incorporated |
Combination therapy for the treatment of neoplasms
|
|
CA3040025C
(en)
|
2003-06-12 |
2023-01-10 |
Alnylam Pharmaceuticals, Inc. |
Conserved hbv and hcv sequences useful for gene silencing
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
EP2325314B1
(en)
|
2004-09-24 |
2014-08-20 |
Alnylam Pharmaceuticals, Inc. |
Targeting opposite strand replication intermediates of single-stranded viruses by RNAI
|
|
AU2005319306B9
(en)
|
2004-12-22 |
2012-04-05 |
Alnylam Pharmaceuticals, Inc. |
Conserved HBV and HCV sequences useful for gene silencing
|
|
PT1912675E
(pt)
|
2005-07-25 |
2014-05-09 |
Emergent Product Dev Seattle |
Moléculas de ligaçao especificas para cd37 e especificas para cd20
|
|
MX380352B
(es)
|
2006-06-12 |
2025-03-12 |
Aptevo Res & Development Llc |
Proteinas de union multivalentes monocatenarias con funcion efectora.
|
|
CN101541950A
(zh)
|
2006-07-13 |
2009-09-23 |
惠氏公司 |
糖蛋白的产生
|
|
DK2548438T3
(en)
|
2006-11-08 |
2015-10-19 |
Veritas Bio LLC |
IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
|
|
CN101990439A
(zh)
*
|
2007-07-06 |
2011-03-23 |
特鲁比昂药品公司 |
具有置于c末端的特异性结合结构域的结合肽
|
|
RS51975B
(sr)
|
2008-04-11 |
2012-02-29 |
Emergent Product Development Seattle Llc. |
Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom
|
|
CA2761106C
(en)
|
2009-05-05 |
2019-01-15 |
Miragen Therapeutics |
Lipophilic polynucleotide conjugates
|
|
AU2010258875A1
(en)
|
2009-06-08 |
2012-01-19 |
Miragen Therapeutics |
Chemical modification motifs for miRNA inhibitors and mimetics
|
|
NZ602538A
(en)
*
|
2010-04-01 |
2014-03-28 |
Pharmanest Ab |
Thermogelling anaesthetic compositions
|
|
EP2635681B8
(en)
|
2010-11-05 |
2017-10-04 |
Miragen Therapeutics, Inc. |
Base modified oligonucleotides
|
|
AR084319A1
(es)
|
2010-12-15 |
2013-05-08 |
Miragen Therapeutics |
INHIBIDORES DE microARN (miARN O miR) QUE COMPRENDEN NUCLEOTIDOS BLOQUEADOS
|
|
AU2012242761A1
(en)
|
2011-04-12 |
2013-10-31 |
Beth Israel Deaconess Medical Center, Inc. |
Micro-RNA inhibitors and their uses in disease
|
|
US9018188B2
(en)
|
2011-09-13 |
2015-04-28 |
Ottawa Hospital Research Institute |
MicroRNA inhibitors
|
|
CN104685056A
(zh)
|
2012-06-21 |
2015-06-03 |
米拉根医疗股份有限公司 |
包含锁核酸基序的基于寡核苷酸的抑制剂
|
|
CA2902571A1
(en)
|
2013-03-15 |
2014-09-18 |
MiRagen Therapeutics, Inc. |
Bridged bicyclic nucleosides
|
|
US10172916B2
(en)
|
2013-11-15 |
2019-01-08 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating heart failure with agonists of hypocretin receptor 2
|
|
US10772974B2
(en)
|
2013-11-18 |
2020-09-15 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
|
JP6637961B2
(ja)
|
2014-08-04 |
2020-01-29 |
ミラゲン セラピューティクス， インコーポレイテッド |
Ｍｙｈ７ｂの阻害剤およびその使用
|
|
JP6837963B2
(ja)
|
2014-09-08 |
2021-03-03 |
ミラゲン セラピューティクス， インコーポレイテッド |
Ｍｉｒ−２９模倣物およびその使用
|
|
JP2018503646A
(ja)
|
2015-01-20 |
2018-02-08 |
ミラゲン セラピューティクス， インコーポレイテッド |
ｍｉＲ−９２阻害剤およびその使用
|
|
WO2016197024A2
(en)
|
2015-06-05 |
2016-12-08 |
MiRagen Therapeutics, Inc. |
Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
|
|
BR112018005573A2
(pt)
|
2015-09-21 |
2019-01-22 |
Aptevo Research And Development Llc |
?polipeptídeos de ligação a cd3?
|
|
US10357543B2
(en)
|
2015-11-16 |
2019-07-23 |
Ohio State Innovation Foundation |
Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein
|
|
NZ749593A
(en)
|
2016-06-20 |
2025-10-31 |
Univ Leland Stanford Junior |
Circular rnas and their use in immunomodulation
|
|
UY37376A
(es)
|
2016-08-26 |
2018-03-23 |
Amgen Inc |
Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
|
|
ES2659845B1
(es)
|
2016-09-19 |
2019-01-04 |
Univ Valencia |
Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
|
|
UY38003A
(es)
|
2017-12-12 |
2019-06-28 |
Amgen Inc |
Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
|
|
EP3765619B1
(en)
|
2018-03-14 |
2024-10-09 |
Beth Israel Deaconess Medical Center |
Inhibitors of micro-rna 22
|
|
KR20210102932A
(ko)
|
2018-12-10 |
2021-08-20 |
암젠 인크 |
Pnpla3 발현을 억제하기 위한 rnai 작제물 및 이의 사용 방법
|
|
JP2022511866A
(ja)
|
2018-12-10 |
2022-02-01 |
アムジエン・インコーポレーテツド |
化学修飾されたＲＮＡｉコンストラクト及びその使用
|
|
TW202111124A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
|
|
CA3150758A1
(en)
|
2019-08-13 |
2021-02-18 |
Amgen Inc. |
Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
|
|
US20230078200A1
(en)
|
2019-12-09 |
2023-03-16 |
Amgen Inc. |
RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
|
|
WO2021234607A1
(en)
|
2020-05-20 |
2021-11-25 |
St. Jude Children's Research Hospital |
Detection of alzheimer's disease using specific biomarkers
|
|
US20230279399A1
(en)
|
2020-06-01 |
2023-09-07 |
Amgen Inc. |
Rnai constructs for inhibiting hsd17b13 expression and methods of use thereof
|
|
EP3929295A1
(en)
|
2020-06-26 |
2021-12-29 |
Universitat Pompeu Fabra |
Artificial rnas for modulating rna fragments
|
|
CR20230126A
(es)
|
2020-08-13 |
2023-05-03 |
Amgen Inc |
CONSTRUCCIONES DE iARN Y MÉTODOS PARA INHIBIR LA EXPRESIÓN DE MARC1
|
|
KR20230104200A
(ko)
|
2020-11-05 |
2023-07-07 |
암젠 인크 |
LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
|
|
WO2023278295A1
(en)
|
2021-06-29 |
2023-01-05 |
The Broad Institute, Inc. |
Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
|
|
CA3234369A1
(en)
|
2021-10-05 |
2023-04-13 |
Amgen Inc. |
Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
|
|
WO2023069754A2
(en)
|
2021-10-22 |
2023-04-27 |
Amgen Inc. |
Rnai constructs for inhibiting gpam expression and methods of use thereof
|
|
IL317825A
(en)
|
2022-07-25 |
2025-02-01 |
Amgen Inc |
RNA interference constructs and methods for inhibiting fam13a expression
|
|
EP4353823A1
(en)
|
2022-10-12 |
2024-04-17 |
Resalis Therapeutics S.r.l. |
Inhibitors of micro-rna 22
|
|
IL321194A
(en)
|
2022-12-16 |
2025-07-01 |
Amgen Inc |
RNA interference constructs for inhibiting TTR expression and methods for using them
|
|
WO2025260042A1
(en)
|
2024-06-14 |
2025-12-18 |
Amgen Inc. |
Rnai constructs and methods for inhibiting cnr1 expression
|